Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).

2-year RFS with ctDNA-informed escalation was 52% vs 61% with standard of care (HR 1.11, 90% CI 0.83-1.48; P=0.6). 3-year RFS was similar for FOLFOXIRI vs FOLFOX/CAPOX (47% vs 51%; HR 1.09, P=0.7). Recurrence risk increased with ctDNA burden (3-year RFS 78%, 63%, 36%, and 22% across MTM/mL quartiles; P<0.01). Escalation, including to FOLFOXIRI, did not improve RFS.

ASCO Annual Meeting 2025PubMed 41115959